Latest Regulatory Milestones News

Richmond Vanadium Technology has appointed Seth McCann as General Manager for Development, Approvals & Studies, positioning the company to advance critical environmental and regulatory milestones for its Queensland vanadium project.

Memphasys delivered a record $150,000 quarterly revenue, secured its largest Felix™ supply contract with Monash IVF, and expanded into UK and Southeast Asian IVF markets, positioning for accelerated growth in FY27.

Neurotech International has locked in a $3.15 million secured loan against its anticipated R&D tax incentives to fund pivotal Phase III autism trials and ongoing operations.

Phoslock Environmental Technologies increased production significantly in the June quarter but faced a higher operating cash flow deficit and ongoing legal disputes.

Neurotech International has secured FDA clearance for its Investigational New Drug application for NTI164, enabling clinical development in the US and advancing its global registration and commercialisation plans.

Vectus Biosystems has appointed Cardinal Health Regulatory Services as its US regulatory agent to manage FDA submissions for its lead fibrosis drug VB0004, marking a pivotal step towards clinical development in the US.

Cleo Diagnostics (ASX:COV) has entered the analytical validation phase for its ovarian cancer test, progressing toward an FDA 510(k) submission expected in early 2027.

Anson Resources has clinched approval for its Small Scale Mining Operation at its Green River Lithium Project, clearing the way for a 10,000 tpa lithium carbonate plant in Utah. With all major permits in hand, the company moves closer to refining costs and advancing project financing.

Odyssey Gold’s Stage 1 Scoping Study for the Tuckanarra Project outlines a low-capital, high-margin open-pit mining operation producing 79,000 ounces of gold over 29 months with pre-tax cashflows of A$180 million at A$6,000/oz gold price.

Chariot Resources has secured additional exploration licence transfers in Nigeria and increased its convertible loan to fund regulatory costs, pushing its Nigerian lithium acquisition closer to completion.

Dimerix will provide continued access to its investigational drug DMX-200 for eligible patients with focal segmental glomerular sclerosis after completing the pivotal ACTION3 Phase 3 trial, supporting ongoing treatment ahead of regulatory approval.

Sibelco Silica Pty Ltd has exercised its call option to inject an additional $4.4 million into the Diatreme joint venture, restoring ownership stakes and supporting key project milestones for the Northern Silica Project in Far North Queensland.